RSS
8 Nov 2019

Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting

Author: admintech | Filed under: Press Release

INDIANAPOLIS, Nov. 8, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) annual meeting…

This entry was posted on Friday, November 8th, 2019 at 7:14 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»